Compositions comprising urolithins and uses thereof for the stimulation of insulin secretion
The present invention relates to a composition comprising urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, for the stimulation of insulin secretion, and to the use of a compound chosen among urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, intended for the stimulation of insulin secretion. The present invention also relates to a composition comprising an effective amount of urolithin B, urolithin C, urolithin D, or a combination thereof, for the treatment or the prevention of diabetes mellitus, and in particular for the treatment or the prevention of type 2 diabetes, and to the use of a compound chosen among urolithin B, urolithin C, urolithin D, and a combination thereof, intended for the treatment or the prevention of diabetes mellitus, and in particular of type 2 diabetes.
1. A composition comprising urolithin C and a second compound able to stimulate insulin secretion selected from the group consisting of sulfonylureas, GLP-1 analogs, and DPP4 inhibitors.
2. The composition of claim 1 , wherein the compound able to stimulate insulin secretion is a sulfonylurea.
3. The composition of claim 2 , wherein the compound able to stimulate insulin secretion is a sulfonylurea selected from the group consisting of Metahexamide, Glibenclamide (Glyburide), Carbutamide, Acetohexamide, Chlorpropamide, Tolbutamide, Tolazamide, Glipizide, Gliclazide, Glibornuride, Gliquidone, Glisoxepide, Glyclopyramide, and Glimepiride.
4. The composition of claim 3 , wherein the compound able to stimulate insulin secretion is Glibenclamide.
5. The composition of claim 1 , wherein the compound able to stimulate insulin secretion is a GLP-1 analog.
6. The composition of claim 5 , wherein the compound able to stimulate insulin secretion is a GLP-1 analog selected from the group consisting of exenatide and liraglutide.
7. The composition of claim 6 , wherein the compound able to stimulate insulin secretion is exenatide.
8. The composition of claim 1 , wherein the compound able to stimulate insulin secretion is a DPP4 inhibitor.
9. The composition of claim 8 , wherein the compound able to stimulate insulin secretion is a DPP4 inhibitor selected from the group consisting of Alogliptin, Gemigliptin, Linagliptin, Saxagliptin, Sitagliptin, and Vildagliptin.
10. A pharmaceutical formulation for the treatment of diabetes mellitus comprising an effective amount of the composition of claim 1 in a pharmaceutically acceptable vehicle.
11. A food product or a nutritional supplement for the stimulation of insulin secretion comprising an effective amount of the composition of claim 1 and a nutritionally acceptable vehicle.
12. A swallowable tablet, chewable tablet, effervescent tablet, capsule, pill, powder, granule, oral solution, oral suspension, sublingual dosage form, or buccal dosage form, comprising the composition of claim 1 and a carrier that is acceptable for nutritional usage.
13. A pharmaceutical formulation, food product, or a nutritional supplement comprising the composition of claim 1 for the treatment of a patient chosen from among the group consisting of a prediabetic patient, a patient whose fasting glycemia is comprised between 1 and 1.25 g L −1 and a patient whose post-prandial glycemia is comprised between 1.40 and 1.99 g L −1 .
14. A pharmaceutical formulation, food product, or a nutritional supplement comprising the composition of claim 1 for the treatment of a diabetic patient, a patient whose fasting glycemia is equal or superior to 1.26 g·L −1 and a patient whose post-prandial glycemia is equal or superior to 2 g·L −1 .
15. A combination product comprising the components of the composition of claim 1 , provided for simultaneous, separate or sequential use.